Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: A phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial

Abstract

Lack of clinical benefits with GSK3772847 was likely due to the small sample size, highlighting the need for larger prospective studies.